BPC, Body Protection Compound
Evidence Grade C — Moderate human evidence. 170 published studies, 28 human. 0 registered clinical trials.
Pentadecapeptide BPC is an older name for the same compound known as BPC-157. The evidence base, regulatory status, and limitations are identical. See the BPC-157 entry for the full assessment.
170 published studies: 28 human, 91 animal, 17 in-vitro, 29 reviews
This entry reflects historical nomenclature for the compound more commonly known as BPC-157. The evidence base, regulatory status, and limitations described for BPC-157 (#81) apply identically to this compound. See compound #81 for the full assessment.
No marketing authorisation. No human Phase III trials. No established human dosing or safety profile.
Identical to BPC-157 (#81). Research in animal models has proposed multiple mechanisms. No mechanisms have been validated in controlled human trials.
This compound is identical to BPC-157. All information in the BPC-157 entry applies here. In brief: over 100 animal studies (predominantly from a single research group at the University of Zagreb) show positive results for tissue repair, but there are no completed human Phase III trials, no established human dosing or safety profile, and products from unregulated sources lack pharmaceutical quality assurance.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
TB-500 has no marketing authorisation from any regulatory agency. No human clinical trials of TB-500 specifically have been conducted. The evidence base relies on animal studies of both TB-500 and its parent molecule thymosin beta-4, which are not pharmacologically equivalent. TB-500 is prohibited by WADA and is known from equine and greyhound racing contexts. Products available through unregulated channels lack pharmaceutical quality assurance. The absence of any human safety or efficacy data means that the compound's effects, risks, interactions, and appropriate dosing in humans are unknown.
ARA-290 (cibinetide) has no marketing authorisation. Phase II trials in sarcoidosis neuropathy showed improvements in corneal nerve fibre density, and a Phase II trial in diabetic neuropathy reported improved metabolic parameters and pain scores. The FDA granted Fast Track designation for sarcoidosis neuropathy. No Phase III trials have been completed. The compound represents an investigational approach to tissue repair that is distinct from existing erythropoietin-based therapies, but its clinical development remains at an early stage.
Chonluten has no marketing authorisation from any major regulatory agency. No human clinical trials have been conducted. The evidence base consists of cell culture studies, including one Western-collaborated publication. The Western-collaborated study represents a higher standard of evidence than many Khavinson bioregulator publications, but remains a single in vitro study without clinical confirmation. Products available through unregulated channels lack pharmaceutical quality assurance.
